Clinical Report: Utilizing Intra- and Peritumoral Radiomics to Assess HER2 Status
Overview
This study evaluates the use of intra- and peritumoral radiomics features from contrast-enhanced mammography (CEM) to predict equivocal HER2 (IHC 2+) status in breast cancer patients. The developed nomogram demonstrated superior predictive performance compared to traditional models, highlighting its potential for preoperative assessment.
Background
Accurate identification of HER2 status is crucial for the treatment and prognosis of breast cancer, as HER2-positive cases require targeted therapies. The equivocal IHC 2+ status complicates this process, necessitating additional testing like FISH, which can be time-consuming and costly. This study explores a non-invasive approach using CEM radiomics to enhance HER2 status prediction.
Data Highlights
Cohort
AUC
Internal Test
0.893
Prospective Test
0.840
Key Findings
The study included 131 breast cancer patients with equivocal HER2 (IHC 2+) status.
Five radiomics signatures were established based on intratumoral and peritumoral regions.
The nomogram achieved an AUC of 0.893 in the internal test cohort.
Calibration curves and decision curve analysis indicated favorable predictive performance of the nomogram.
This approach offers a non-invasive alternative to traditional HER2 testing methods.
Clinical Implications
The nomogram developed in this study can assist clinicians in predicting HER2 status preoperatively, potentially reducing the need for invasive testing. This tool may streamline the treatment decision-making process for patients with equivocal HER2 status.
Conclusion
The integration of radiomics features from CEM into a predictive nomogram shows promise for improving the assessment of equivocal HER2 status in breast cancer, potentially enhancing patient management strategies.
